Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
JNK inhibitor
SP600125 is a JNK inhibitor with IC50=40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3.- Peiling Zhang, .et al. , Regen Biomater, 2023, Sep 7:10:rbad079 PMID: 38020237
- Tetsuya Kouno, .et al. , J Biol Chem, 2022, Jul;298(7):102056 PMID: 35605662
- Mark P Roberto, .et al. , Immunity, 2021, Aug 10;54(8):1807-1824.e14 PMID: 34380064
- Yang PM, .et al. , Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078
- Byungki Jang, .et al. , Int J Mol Sci, 2017, Nov; 18(11): 2258 PMID: 29077055
- Yuki Haga, .et al. , PLoS One, 2017, 12(3): e0174153 PMID: 28323861
- Jia-Shiuan Tsai, .et al. , PLoS One, 2016, 11(1): e0147011 PMID: 26751215
- Choe YJ, .et al. , Int J Oncol., 2014, 44(3):761-8. PMID: 24366007
-
JNK inhibitor
AS 602801 is a novel, orally active, Jun Kinase Inhibitor.- Shuai Zhang, .et al. , J Cell Mol Med, 2021, Apr;25(8):4062-4072 PMID: 33609076
- Kuramoto K, .et al. , Anticancer Res, 2018, Sep;38(9):5093-5099 PMID: 30194154
-
JNK inhibitor
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.- Jacob Insua‐Rodriguez, .et al. , EMBO Mol Med, 2018, Oct; 10(10): e9003 PMID: 30190333
-
JNK Inhibitor IX
TCS JNK 5a is a highly selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38α respectively).
-
JNK Inhibitor
JNK-IN-8 is the first irreversible JNK inhibitor for JNK1, JNK2 and JNK4 with IC50 of 4.7 nM, 18.7 nM and 1 nM, respectively- Mark P Roberto, .et al. , Immunity, 2021, Aug 10;54(8):1807-1824.e14 PMID: 34380064
-
JNK inhibitor
CC-930 is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ?? 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ?? 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively -
JNK inhibitor
CC-401 hydrochloride is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. -
JNK inhibitor
JIP-1 (153-163) is a peptide inhibitor of c-Jun N-terminal kinase (JNK), based on residues 153-163 of JNK-interacting protein-1 (JIP-1). Binds to JNK with affinity in the micromolar range and minimally inhibits p38 and ERK. -
JNK inhibitor
c-JUN peptide is a peptide comprising residues 33 - 57 of the JNK binding (δ) domain of human c-Jun. -
JNK inhibitor
TCS JNK 6o is a ATP-competitive and selective c-Jun N-terminal kinase (JNK) inhibitor. -
JNK3 inhibitor
IQ-1S is a Selective JNK3 inhibitor with IC50 value of 390, 360 and 87 nM for JNK1, 2 and 3 respectively. -
NF-κB inhibitor
Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B is also a regulator of skeletal muscle mass. -
JNK inhibitor
CC-90001 is a potent and selective JNK inhibitor. CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis -
Endoplasmic Reticulum Stress Inhibitor
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an inhibitor of endoplasmic reticulum (ER) stress that significantly downregulates pro-apoptotic molecules, including caspase-3 and caspase-12. Additionally, it suppresses ERK signaling, contributing to its cytoprotective and anti-apoptotic effects. -
Microglial inhibitor
Inflachromene is a microglial inhibitor that exerts anti-inflammatory effects by directly binding to high mobility group box proteins HMGB1 and HMGB2. Through this interaction, it effectively downregulates the proinflammatory activities of HMGB proteins, leading to reduced microglial activation and neuronal damage. Inflachromene holds promise as a therapeutic candidate for the treatment of neuroinflammatory disorders, including neurodegenerative diseases and central nervous system injuries. -
CDK Inhibitor
Aloisine A is a potent cyclin-dependent kinase (CDK) inhibitor, exhibiting IC50 values of 0.15 μM for CDK1/cyclin B, 0.12 μM for CDK2/cyclin A, 0.4 μM for CDK2/cyclin E, and 0.16 μM for CDK5/p35. In addition to its CDK inhibitory effects, Aloisine A also inhibits GSK-3α and GSK-3β with IC50 values of 0.5 μM and 1.5 μM, respectively. Notably, it enhances the activity of wild-type and mutant CFTR with submicromolar affinity through a cAMP-independent mechanism, making it a valuable tool for research related to cystic fibrosis and CFTR-related disorders. -
JNK Inhibitor
(3S)-Tanzisertib hydrochloride is a selective inhibitor of c-Jun N-terminal kinases (JNK), demonstrating IC50 values of 61, 7, and 6 nM for JNK1, JNK2, and JNK3, respectively. This compound also exhibits inhibition of ERK1, p38α, and EGFR with IC50 values of 0.48, 3.4, and 0.38 μM, respectively. (3S)-Tanzisertib hydrochloride effectively reduces LPS-induced TNFα production in an acute rat pharmacokinetic-pharmacodynamic model, making it a valuable tool in idiopathic pulmonary fibrosis research and other inflammatory disease studies. -
JNK Inhibitor, ERK Inhibitor, TGFβ signaling Activator
(+)-Columbianetin targets JNK and ERK signaling pathways while acting as a TGFβ signaling activator. This compound effectively inhibits UVA-induced phosphorylation of JNK and ERK, decreases MMP-1 production, and reverses collagen degradation. In addition, it mitigates UVA-mediated suppression of Smad2/3 phosphorylation and translocation, providing protective effects against UV-induced cellular damage. (+)-Columbianetin is an essential tool for research focused on skin aging and oxidative stress responses in keratinocytes. -
p38/JNK Inhibitor
LL-Z1640-4 is a selective inhibitor of p38 and JNK signaling pathways, demonstrating significant efficacy in attenuating their activation in hepatocellular carcinoma (HCC) cells following MLK4 siRNA transfection. This compound effectively reduces reactive oxygen species (ROS) production associated with MLK4 knockdown and subsequently decreases apoptosis in these HCC cells. LL-Z1640-4 serves as a valuable tool for investigating the roles of p38 and JNK in cancer biology and therapeutic interventions. -
JNK Inhibitor
JNK-IN-17 is a selective and potent inhibitor of c-Jun N-terminal kinase (JNK), demonstrating IC50 values of 0.039 μM and 0.079 μM for JNK1 and JNK3, respectively. It effectively inhibits c-Jun phosphorylation with an IC50 of 0.082 μM in Streptozotocin-induced INS-1 pancreatic islet β cells. Additionally, JNK-IN-17 exhibits low interaction potential, showing an inhibition rate of ≤ 33% on major cytochrome P450 subtypes in human liver microsomes. This compound is valuable for research applications related to neurological and metabolic disorders, including Parkinson's disease. -
JNK Inhibitor
Cyy-272 is a potent orally active inhibitor of c-Jun N-terminal kinase (JNK), exhibiting IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. This compound demonstrates significant anti-inflammatory properties by inhibiting JNK phosphorylation, effectively mitigating acute lung injury induced by lipopolysaccharide. Additionally, Cyy-272 reduces inflammation in cardiomyocytes and cardiac tissues affected by high lipid concentrations, contributing to decreased cardiac hypertrophy, fibrosis, and apoptosis. It is valuable for research into the mechanisms of obese cardiomyopathy and related cardiovascular disorders. -
JNK2/3 Inhibitor
YL5084 is a covalent inhibitor targeting JNK2 and JNK3, demonstrating selectivity for these isoforms with IC50 values of 70 nM and 84 nM, respectively, while showing significantly reduced activity against JNK1 at 2173 nM. This compound exhibits JNK2-independent antiproliferative effects and effectively induces apoptosis without reliance on JNK2 pathways. YL5084 serves as a valuable tool for research into cellular signaling and cancer biology, particularly in studies focusing on the role of JNK isoforms in tumor growth and survival. -
JNK3 Inhibitor
JNK3 inhibitor-5 is a selective inhibitor targeting JNK3, exhibiting a potent IC50 of 0.379 nM. This compound demonstrates significant neuroprotective activity by safeguarding neuronal cells from amyloid beta-induced apoptosis. Additionally, JNK3 inhibitor-5 is characterized by high cell permeability and is predicted to effectively cross the blood-brain barrier, making it a valuable tool for studying neurological disorders and related therapeutic applications. -
TLR4/JNK/NF-κB Inhibitor
TLR4-IN-2 is an inhibitor targeting TLR4, JNK, and NF-κB pathways. It demonstrates anti-inflammatory properties by reducing nitric oxide production in LPS-stimulated RAW264.7 cells, with an IC50 of 23.2 µM. By inhibiting TLR4 expression and diminishing JNK phosphorylation, TLR4-IN-2 effectively suppresses NF-κB activation and the transcription of inflammation-related genes, leading to lower levels of iNOS, COX-2, and various inflammatory mediators. This compound shows potential for investigating therapeutic strategies in inflammatory diseases such as rheumatoid arthritis and other inflammatory disorders. -
JNK/c-Met Inhibitor
JNK-IN-16 is a potent inhibitor of both JNK and c-Met, exhibiting IC50 values of 72 nM and 120 nM, respectively. This compound demonstrates significant anti-cancer activity, making it valuable for research in cancer biology and therapeutic development. Its dual inhibition profile allows for exploration in signaling pathways associated with tumor progression and metastasis. -
JNK3 Inhibitor
JNK3-IN-10 is a selective inhibitor of JNK3, demonstrating an IC50 value of 0.257 nM and exhibiting over 400-fold selectivity over JNK1. This compound effectively disrupts the JNK3-mediated signaling pathway in response to TGF-β1, leading to the inhibition of c-Jun phosphorylation and a reduction in pro-fibrotic marker expression while restoring E-cadherin levels. Its low cytotoxicity profile, along with anti-fibrotic, cytoprotective, and renoprotective properties, makes JNK3-IN-10 a valuable tool for investigating chronic kidney disease, glomerulosclerosis, and adriamycin-induced nephropathy. -
ERK/JNK Inhibitor
Ambuic acid is a potent inhibitor targeting the ERK/JNK pathway, demonstrating notable anti-inflammatory effects. It displays significant antimicrobial activity against Staphylococcus aureus, with an IC50 value of 43.9 μM for the ATCC 6538 strain. Additionally, Ambuic acid inhibits the biosynthesis of cyclic peptide quorum sensing molecules in gram-positive bacteria, making it a valuable compound for research in antimicrobial and anti-inflammatory applications. -
JNK Inhibitor
JNK-9L is an ATP-competitive inhibitor targeting c-Jun N-terminal kinases (JNK1 and JNK3), exhibiting IC50 values of 0.099 and 0.148 μM, respectively. This compound effectively inhibits c-jun phosphorylation and reduces reactive oxygen species (ROS) generation induced by Streptozotocin with an IC50 of 0.8 nM. JNK-9L is particularly relevant for research into neurodegenerative diseases, including Parkinson’s disease, facilitating investigations into the therapeutic modulation of JNK pathways. -
JNK Inhibitor
JNK-IN-26 is a potent inhibitor of c-Jun N-terminal kinase (JNK), a key signaling enzyme involved in various cellular processes such as apoptosis, inflammation, and stress response. This compound exhibits significant biological activity by selectively inhibiting JNK signaling pathways, making it a valuable tool for studying JNK-related mechanisms in cellular and molecular biology. JNK-IN-26 is utilized in research applications focused on cancer, neurodegenerative diseases, and other conditions involving JNK activation. -
CDK/GSK3β/JNK Inhibitor
Indirubin-3′-oxime (IDR3O) is a synthetic derivative of indirubin that functions as a potent inhibitor of cyclin-dependent kinases (CDKs), glycogen synthase kinase 3β (GSK3β), and all three isoforms of c-Jun N-terminal kinases (JNK1, JNK2, JNK3). It demonstrates inhibitory activity with IC50 values of 0.8 μM, 1.4 μM, and 1.0 μM for each JNK isoform, respectively. Indirubin-3′-oxime is also known to promote chondrocyte height growth through the activation of Wnt/β-catenin signaling, making it relevant for studies in cellular growth and differentiation. -
JNK Inhibitor
J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3), exhibiting an IC50 value of 40 nM and a remarkable 2500-fold selectivity over JNK1α1 and JNK2α2 isoforms. This compound demonstrates significant neuroprotective activity in vitro, making it a valuable tool for researching neurodegenerative diseases and their therapeutic interventions. -
JNK Inhibitor
SR-3306 is a selective pan-JNK (JNK1/2/3) inhibitor with notable brain-penetrating properties. It serves as a neuroprotective agent, making it valuable for investigating neurodegenerative diseases such as Parkinson's disease, as well as conditions related to ischemia/reperfusion (I/R) injury and obesity. Its targeted inhibition of JNK pathways offers potential insights into therapeutic strategies for these disorders. -
JNK3 Inhibitor
JNK3 inhibitor-4 is a selective inhibitor targeting JNK3 (IC50 = 1.0 nM), derived from a 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile scaffold. It demonstrates remarkable selectivity over JNK1 (IC50 = 143.9 nM) and JNK2 (IC50 = 298.2 nM). This compound exhibits neuroprotective properties and shows potential for effective delivery across the blood-brain barrier, making it valuable for research in neurodegenerative diseases and other neurological disorders. -
JNK Inhibitor
JNK3 inhibitor-1 is a potent and selective inhibitor of c-Jun N-terminal kinase 3 (JNK3), exhibiting an IC50 of 0.005 μM. It demonstrates oral bioavailability and the ability to penetrate the blood-brain barrier, making it suitable for neurological research. JNK3 inhibitor-1 is utilized in studies investigating the role of JNK3 in neurodegenerative disorders and various cellular processes. -
JNK1 Inhibitor
JNK-1-IN-3 is a selective inhibitor of JNK1 that effectively downregulates JNK1 gene expression and decreases the levels of its phosphorylated form. This compound concurrently reduces the expression of key downstream targets, including c-Jun and c-Fos, while enhancing p53 activity. JNK-1-IN-3 demonstrates significant antiproliferative effects, especially against renal and breast cancer cell lines, showcasing both in vitro and in vivo anticancer activity, making it a valuable tool for cancer research and therapeutic investigations. -
JNK Inhibitor
JNK-IN-11 is a selective JNK inhibitor, exhibiting IC50 values of 2.2 µM, 21.4 µM, and 1.8 µM for JNK1, JNK2, and JNK3, respectively. This compound demonstrates significant potential in research applications targeting neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, by modulating pathways involved in cell stress and apoptosis. JNK-IN-11 serves as a valuable tool for investigating therapeutic strategies in these conditions. -
JNK Inhibitor
JNK-IN-13 is a selective inhibitor of the c-Jun N-terminal kinases (JNK), demonstrating IC50 values of 290 nM for JNK3 and 500 nM for JNK2. This compound exhibits significant biological activity in modulating cellular stress responses, apoptosis, and inflammation pathways. JNK-IN-13 is valuable for research applications focused on cancer, neurodegenerative diseases, and metabolic disorders, providing insights into JNK signaling mechanisms. -
JNK Inhibitor
Salicortin is a phenolic glycoside that functions as a JNK inhibitor. It effectively inhibits osteoclast differentiation and bone resorption by down-regulating the JNK and NF-κB/NFATc1 signaling pathways. Salicortin exhibits a range of biological activities, including anti-amnesic, anti-adipogenic, and immune-modulatory effects, making it a valuable tool for research in bone metabolism, neurobiology, and immunology. -
JNK/CYP Inhibitor
JNK-IN-14 is a potent inhibitor of the c-Jun N-terminal kinase (JNK) family, demonstrating IC50 values of 1.81 nM for JNK1, 12.7 nM for JNK2, and 10.5 nM for JNK3. This compound effectively induces early apoptosis and causes cell cycle arrest in the G2/M phase. Additionally, JNK-IN-14 exhibits a modest inhibition of beclin-1 expression in K562 leukemia cells, indicating its potential application in cancer research and therapeutic strategies targeting JNK signaling pathways. -
JNKs Inhibitor
(-)-Zuonin A is a selective inhibitor of c-Jun N-terminal kinases (JNKs), demonstrating IC50 values of 1.7 μM, 2.9 μM, and 1.74 μM for JNK1, JNK2, and JNK3, respectively. As a naturally occurring lignin, it exhibits potent inhibitory activity, making it a valuable reagent for studies investigating JNK signaling pathways. This compound is applicable in research areas including cancer biology, neuroprotection, and inflammation.
